Retension completes upsized IPO for hypertension drug RTN-001
Retension Pharmaceuticals raised $45.1 million net through an upsized IPO in October 2026 to fund clinical trials. Stock began trading on Nasdaq under the symbol RTSN on October 9.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed